CYCLO THERAPEUTICS, INC.: 10-Q filed 2017-11-09

Name: CYCLO THERAPEUTICS, INC.: 10-Q filed 2017-11-09
Creator: CYCLO THERAPEUTICS, INC.

What CYCLO THERAPEUTICS, INC. reported in its quarterly report filed 2017-11-09 (fiscal Q3 2017): 25 published measures, 64 facts as tagged in accession 0001437749-17-018879.

This filing

Form: 10-Q (quarterly report)
Filed: 2017-11-09
Fiscal period: fiscal Q3 2017
Accession: 0001437749-17-018879 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All CYCLO THERAPEUTICS, INC. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

Period	Value	Unit	Days
At 2017-09-30	2,169,856	USD
At 2016-12-31	1,868,545	USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

Period	Value	Unit	Days
At 2017-09-30	1,039,685	USD
At 2016-12-31	1,526,003	USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

Period	Value	Unit
At 2017-09-30	1,342,642	USD
At 2016-12-31	960,197	USD
At 2016-09-30	1,270,046	USD
At 2015-12-31	1,842,233	USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

Period	Value	Unit	Days
2017-07-01 to 2017-09-30	-633,749	USD	92
2017-01-01 to 2017-09-30	-2,448,993	USD	273
2016-01-01 to 2016-12-31	-4,223,841	USD	366
2016-07-01 to 2016-09-30	-1,614,933	USD	92
2016-01-01 to 2016-09-30	-3,391,865	USD	274

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

Period	Value	Unit	Days
2017-01-01 to 2017-09-30	-2,076,426	USD	273
2016-01-01 to 2016-12-31	-2,950,938	USD	366
2016-01-01 to 2016-09-30	-2,386,557	USD	274

Capital expenditure payments

Cash payments to acquire property, plant and equipment. This taxonomy concept does not capture every form of investment or acquisition.

Period	Value	Unit	Days
2017-01-01 to 2017-09-30	7,503	USD	273
2016-01-01 to 2016-09-30	9,343	USD	274

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

Period	Value	Unit	Days
2017-01-01 to 2017-09-30	2,436,055	USD	273
2016-01-01 to 2016-09-30	1,799,000	USD	274

Investing cash flow

Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.

Period	Value	Unit	Days
2017-01-01 to 2017-09-30	22,816	USD	273
2016-01-01 to 2016-09-30	15,370	USD	274

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

Period	Value	Unit	Days
At 2017-09-30	-11,948,600	USD
At 2016-12-31	-9,499,607	USD

Net property, plant and equipment

Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.

Period	Value	Unit	Days
At 2017-09-30	27,225	USD
At 2016-12-31	29,984	USD

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

Period	Value	Unit	Days
2017-01-01 to 2017-09-30	76,030	USD	273
2016-01-01 to 2016-09-30	57,114	USD	274

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

Period	Value	Unit	Days
2017-07-01 to 2017-09-30	-636,898	USD	92
2017-01-01 to 2017-09-30	-2,458,244	USD	273
2016-07-01 to 2016-09-30	-1,610,730	USD	92
2016-01-01 to 2016-09-30	-3,377,752	USD	274

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

Period	Value	Unit	Days
At 2017-09-30	1,965,272	USD
At 2016-12-31	1,635,533	USD

Interest expense

Borrowing costs recognized as interest expense. This is distinct from cash interest paid and may not include every capitalized borrowing cost.

Period	Value	Unit	Days
2016-07-01 to 2016-09-30	6,969	USD	92
2016-01-01 to 2016-09-30	21,722	USD	274

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

Period	Value	Unit	Days
At 2017-09-30	1,130,171	USD
At 2016-12-31	342,542	USD

Net current accounts receivable

Current customer receivables after the allowance for credit loss. The balance is not cash collected or a guarantee of collection.

Period	Value	Unit	Days
At 2017-09-30	94,017	USD
At 2016-12-31	89,667	USD

Net inventory

Inventory carrying amount after applicable valuation and LIFO reserves. It does not establish realizable selling proceeds or inventory turnover without other inputs.

Period	Value	Unit	Days
At 2017-09-30	474,010	USD
At 2016-12-31	497,397	USD

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

Period	Value	Unit	Days
2017-07-01 to 2017-09-30	338,723	USD	92
2017-01-01 to 2017-09-30	1,509,352	USD	273
2016-07-01 to 2016-09-30	311,351	USD	92
2016-01-01 to 2016-09-30	1,254,900	USD	274

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

Period	Value	Unit	Days
At 2017-09-30	72,999,361	shares
At 2016-12-31	66,952,529	shares

Additional paid-in capital

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

Period	Value	Unit	Days
At 2017-09-30	12,980,986	USD
At 2016-12-31	11,018,915	USD

Pre-tax income or loss from continuing operations

Income or loss from continuing operations before income taxes and noncontrolling interests. It excludes discontinued operations and is not net income.

Period	Value	Unit	Days
2017-07-01 to 2017-09-30	-633,749	USD	92
2017-01-01 to 2017-09-30	-2,448,993	USD	273
2016-07-01 to 2016-09-30	-1,614,933	USD	92
2016-01-01 to 2016-09-30	-3,391,865	USD	274

Depreciation expense

Depreciation recognized for the period under this concept. It is a noncash allocation of asset cost and may exclude amortization and depletion reported elsewhere.

Period	Value	Unit	Days
2017-01-01 to 2017-09-30	6,873	USD	273
2016-01-01 to 2016-09-30	92,146	USD	274

Nonoperating income or expense

Total nonoperating income or expense, which can include interest, investment results and other items. A positive value is not operating profit.

Period	Value	Unit	Days
2017-07-01 to 2017-09-30	3,149	USD	92
2017-01-01 to 2017-09-30	9,251	USD	273
2016-07-01 to 2016-09-30	-4,203	USD	92
2016-01-01 to 2016-09-30	-14,113	USD	274

Change in accounts receivable

The cash flow adjustment for the change in receivables during the period. A positive value under this concept means receivables grew and reduced operating cash flow.

Period	Value	Unit	Days
2017-01-01 to 2017-09-30	4,350	USD	273
2016-01-01 to 2016-09-30	68,598	USD	274

Change in inventories

The cash flow adjustment for the change in inventories during the period. A positive value under this concept means inventory grew and reduced operating cash flow.

Period	Value	Unit	Days
2017-01-01 to 2017-09-30	-23,387	USD	273
2016-01-01 to 2016-09-30	-19,758	USD	274

Inspect the source

Entity: CYCLO THERAPEUTICS, INC. / CIK 0000922247
Captured: 2026-09-21T17:17:43.874Z
SEC response SHA-256: 00eb7fd40e8240f18174ace9c17e250765347f97ee2730b0222250298ac67de3

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python

import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0000922247.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))